The company plans to use parts of the proceeds from the offering to pay for the recent settlement with Illumina.
Biocept closed a $14.8 million public offering earlier this year and recently reported ending the second quarter with $2.6 million in cash and cash equivalents.
The firm will sell more than 14 million shares of its common stock for $4.25 per share.
The firm did not disclose how many shares it planned to sell or how much money it expects to raise.
The filing follows the firm's recent close of a $2 million non-convertible debt instrument and CE marking for its tuberculosis test.
Proceeds from the offering, expected to close on or about Aug. 14, could be used to fund acquisitions, to repay existing debts, or for working capital.
The company had previously said that it expected gross proceeds of up to $22.6 million if rights to all 25,000 securities units were exercised.
Proceeds from the offering could be used to fund acquisitions, to repay existing debts, or for working capital.
The company said proceeds will be used for working capital, and may also be used to acquire or invest in complementary businesses or technologies.
The firm has reached a deal with certain investors for the purchase of units comprising OncoCyte common shares and warrants to purchase shares.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.